Education
About Us
Working with TipRanks
Follow Us
Evotec AG (EVO)
NASDAQ:EVO
EVO Stock Chart & Stats
$3.52
-$0.25(-5.45%)
At close: 4:00 PM EST
$3.52
-$0.25(-5.45%)
Day’s Range― - ―
52-Week Range$2.84 - $4.80
Previous CloseN/A
Volume32.72K
Average Volume (3M)186.07K
Market Cap
$1.29B
Enterprise Value$1.40B
Total Cash (Recent Filing)$237.27M
Total Debt (Recent Filing)$484.62M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Apr 01, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding355,755,550
10 Day Avg. Volume383,647
30 Day Avg. Volume186,074
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.49
Price to Sales (P/S)1.78
P/FCF Ratio-12.45
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue1.85
Enterprise Value/Gross Profit17.13
Enterprise Value/Ebitda-15.85
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AI Partnerships And Platform MonetizationBroad pharmaceutical collaborations and expanding AI/ML offerings validate the drug‑discovery platform and increase the potential for milestone and royalty income as partnered programs advance.
Asset Sale ProceedsSandoz's purchase of the EU Just‑Evotec Biologics operations will net approximately €650 million, providing substantial cash that can strengthen the balance sheet and fund strategic investments.
Business Validation And Customer ExpansionValidation by Sandoz combined with an expanding customer roster supports the Just‑Evotec Biologics franchise and may translate into steadier contract wins and revenue growth.
Bears Say
Divestiture Impact On Long-term GrowthDivesting the EU biologics unit may reduce future organic revenue potential from that segment and creates uncertainty about the company’s long‑term growth profile.
Earnings Volatility And Consensus RiskLumpy performance across business units raises the risk of quarterly revenue misses versus analyst expectations and could weigh on the stock until trends become more consistent.
Revenue Softness And Growth MomentumSoft demand across discovery and development services and biologics services highlights fragile growth momentum and increases sensitivity to macroeconomic pressures.
Evotec AG News
EVO FAQ
What was Evotec AG’s price range in the past 12 months?
Evotec AG lowest stock price was $2.84 and its highest was $4.80 in the past 12 months.
What is Evotec AG’s market cap?
Evotec AG’s market cap is $1.29B.
When is Evotec AG’s upcoming earnings report date?
Evotec AG’s upcoming earnings report date is Apr 01, 2026 which is in 51 days.
How were Evotec AG’s earnings last quarter?
Evotec AG released its earnings results on Nov 05, 2025. The company reported -$0.138 earnings per share for the quarter, missing the consensus estimate of -$0.077 by -$0.061.
Is Evotec AG overvalued?
According to Wall Street analysts Evotec AG’s price is currently Overvalued.
Does Evotec AG pay dividends?
Evotec AG pays a Monthly dividend of $0.072 which represents an annual dividend yield of N/A. See more information on Evotec AG dividends here
What is Evotec AG’s EPS estimate?
Evotec AG’s EPS estimate is 0.1.
How many shares outstanding does Evotec AG have?
Evotec AG has 355,755,550 shares outstanding.
What happened to Evotec AG’s price movement after its last earnings report?
Evotec AG reported an EPS of -$0.138 in its last earnings report, missing expectations of -$0.077. Following the earnings report the stock price went down -15.743%.
Which hedge fund is a major shareholder of Evotec AG?
Currently, no hedge funds are holding shares in EVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evotec AG Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.10%
12-Months-Change
Fundamentals
Return on Equity
-17.46%
Trailing 12-Months
Asset Growth
-6.25%
Trailing 12-Months
Company Description
Evotec AG
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
EVO Company Deck
EVO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a challenging environment for Evotec, with significant headwinds in the D&PD segment and overall revenue declines. However, the company showcases strong growth in the Biologics segment, transformational strategic partnerships, and effective cost reduction efforts. These positive developments, particularly the Sandoz deal and asset pipeline progression, suggest an optimistic outlook despite current challenges.View all EVO earnings summariesTechnical Analysis
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
1.82% Other Institutional Investors
98.18% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---